|
|
|
|
| LEADER |
03549nmm a2200361 u 4500 |
| 001 |
EB000366082 |
| 003 |
EBX01000000000000000219134 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9781603273336
|
| 100 |
1 |
|
|a Neve, Kim
|e [editor]
|
| 245 |
0 |
0 |
|a The Dopamine Receptors
|h Elektronische Ressource
|c edited by Kim Neve
|
| 250 |
|
|
|a 2nd ed. 2010
|
| 260 |
|
|
|a Totowa, NJ
|b Humana
|c 2010, 2010
|
| 300 |
|
|
|a XII, 648 p. 69 illus., 6 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Historical Overview: Introduction to the Dopamine Receptors -- Gene and Promoter Structures of the Dopamine Receptors -- Structural Basis of Dopamine Receptor Activation -- Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors -- Dopamine Receptor Subtype-Selective Drugs: D2-Like Receptors -- Dopamine Receptor Signaling: Intracellular Pathways to Behavior -- Dopaminergic Modulation of Glutamatergic Signaling in Striatal Medium Spiny Neurons -- Regulation of Dopamine Receptor Trafficking and Responsiveness -- Dopamine Receptor-Interacting Proteins -- Dopamine Receptor Oligomerization -- Dopamine Receptor Modulation of Glutamatergic Neurotransmission -- Unraveling the Role of Dopamine Receptors In Vivo: Lessons from Knockout Mice -- Dopamine Receptors and Behavior: From Psychopharmacology to Mutant Models -- Dopamine Modulation of the Prefrontal Cortex and Cognitive Function -- In Vivo Imaging of Dopamine Receptors -- Dopamine Receptors and the Treatment of Schizophrenia -- Dopamine Receptor Subtypes in Reward and Relapse -- Dopamine Receptors and the Treatment of Parkinson’s Disease -- Dopamine Receptor Genetics in Neuropsychiatric Disorders
|
| 653 |
|
|
|a Neuroscience
|
| 653 |
|
|
|a Pharmaceutical chemistry
|
| 653 |
|
|
|a Neurosciences
|
| 653 |
|
|
|a Neurology
|
| 653 |
|
|
|a Neurology
|
| 653 |
|
|
|a Human Physiology
|
| 653 |
|
|
|a Human physiology
|
| 653 |
|
|
|a Pharmaceutics
|
| 653 |
|
|
|a Pharmacology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a The Receptors
|
| 028 |
5 |
0 |
|a 10.1007/978-1-60327-333-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-60327-333-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.8
|
| 520 |
|
|
|a Dopamine receptors are among the most validated drug targets for neuropsychiatric disorders such as schizophrenia and Parkinson’s disease, and are potential targets for other disorders such as substance abuse, depression, Tourette’s syndrome, and attention deficit hyperactivity disorder. The new knowledge brought from the creation and characterization of mice deficient in each of the subtypes and the development of increasingly subtype-selective agonists and antagonists has fueled many of the chapters new to this second edition, with the use of knock-out mice and subtype-selective drugs meriting discussion in stand-alone chapters. The field of G protein-coupled receptors has also advanced significantly since the first edition, with a model of GPCR signaling based on linear, compartmentalized pathways having been replaced by a more complex, richer model in which neurotransmitter effects are mediated by a signalplex composed of numerous signaling proteins, including multiple GPCRs, other types of receptors, such as ionotropic receptors, accessory and scaffolding proteins, and effectors. This second edition of Dopamine Receptors will be of interest to neurobiologists, pharmacologists and molecular biologists who study the brain, as well as neurologists working on psychiatric diseases
|